SCHEMBL21657955

SCHEMBL21657955

O=c1c2ccccc2c2cc(-c3c4ccccc4c(-c4ccccc4)c4ccccc34)cc3c4ccccc4c(=O)n1c23

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.41
LMNA P02545 4/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.40
BRD4 O60885 1/20 0.39
DPP4 P27487 1/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
KDM4E B2RXH2 3/20 0.36
RCE1 Q9Y256 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPK8 P45983 1/20 0.36
GAA P10253 3/20 0.36
ALOX15 P16050 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TACR1 P25103 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20227464 0.91 KMT2A (0.43) NPSR1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL21657984 0.87 ALOX5 (0.38) NPSR1BRD4
SCHEMBL17107965 0.86 MAPK1 (0.42) NPSR1LMNAKMT2AMAPK1BRD4
SCHEMBL17108006 0.85 BRD4 (0.42) NPSR1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL17108049 0.85 MAPK1 (0.43) NPSR1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL23131946 0.85 NPSR1 (0.36) NPSR1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL20227610 0.85 KMT2A (0.35) NPSR1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL17107964 0.83 MAPK1 (0.40) NPSR1LMNAMAPK1BRD4HTT
SCHEMBL17107970 0.83 MAPK1 (0.40) NPSR1LMNAMAPK1BRD4HTT
SCHEMBL17107978 0.83 BRD4 (0.46) NPSR1LMNAKMT2ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
EP-3548467-B1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2023-06-21 EP disclosed
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713319-B2 Compounds having valerolactam structures ACE, CYP3A4, CYP2D6 NPSR1 1778/4885LMNA 2666/4885KMT2A 1161/4885
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES ACE, CYP3A4, CYP2D6 NPSR1 1778/4885LMNA 2666/4885KMT2A 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.